AR069281A2 - Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentos - Google Patents
Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentosInfo
- Publication number
- AR069281A2 AR069281A2 ARP080104921A ARP080104921A AR069281A2 AR 069281 A2 AR069281 A2 AR 069281A2 AR P080104921 A ARP080104921 A AR P080104921A AR P080104921 A ARP080104921 A AR P080104921A AR 069281 A2 AR069281 A2 AR 069281A2
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- same
- sustained release
- average molecular
- molecular weight
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 abstract 2
- 229960003765 fluvastatin Drugs 0.000 abstract 2
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composicion farmacéutica, que comprende fluvastatina o una sal farmacéuticamente aceptable de la misma, hidroxipropilmetilcelulosa y un polímero hidrofílico no ionico seleccionado del grupo formado hidroxietilcelulosa con un peso molecular promedio en numero de 90.000 a 1.300.000; hidroxipropilcelulosa con un peso molecular promedio en numero de 370.000 a 1.500.000; y poli(oxido de etileno) con un peso molecular promedio en numero de 100.000 a 500.000; y uso de la misma para preparar medicamentos. Reivindicacion 6: Una composicion farmacéutica de la reivindicacion 1, caracterizada porque comprende de 5 a 50 por ciento en peso de fluvastatina o una sal farmacéuticamente aceptable de la misma, basándose en el peso total de la composicion. Reivindicacion 12: Una composicion farmacéutica de la reivindicacion 1, caracterizada porque la proporcion en peso de hidroxipropilmetilcelulosa a polímero hidrofílico no ionico es de 10:1 a 3:1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17249198A | 1998-10-14 | 1998-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069281A2 true AR069281A2 (es) | 2010-01-13 |
Family
ID=22627919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990105146A AR020780A1 (es) | 1998-10-14 | 1999-10-12 | Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo |
| ARP080104921A AR069281A2 (es) | 1998-10-14 | 2008-11-11 | Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990105146A AR020780A1 (es) | 1998-10-14 | 1999-10-12 | Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1121116B1 (es) |
| JP (2) | JP2002527388A (es) |
| KR (1) | KR100517090B1 (es) |
| CN (1) | CN1196481C (es) |
| AR (2) | AR020780A1 (es) |
| AT (1) | ATE382345T1 (es) |
| AU (1) | AU765475B2 (es) |
| BR (1) | BR9911648A (es) |
| CA (1) | CA2346868C (es) |
| CO (1) | CO5140079A1 (es) |
| CY (1) | CY1107874T1 (es) |
| DE (1) | DE69937891T2 (es) |
| DK (1) | DK1121116T3 (es) |
| ES (1) | ES2297936T3 (es) |
| HK (1) | HK1040920B (es) |
| HU (1) | HUP0104268A3 (es) |
| ID (1) | ID29350A (es) |
| IL (2) | IL142375A0 (es) |
| MY (1) | MY121105A (es) |
| NO (1) | NO327285B1 (es) |
| NZ (1) | NZ511010A (es) |
| PE (1) | PE20001110A1 (es) |
| PL (1) | PL198850B1 (es) |
| PT (1) | PT1121116E (es) |
| RU (1) | RU2259826C2 (es) |
| SK (2) | SK286595B6 (es) |
| TR (1) | TR200101088T2 (es) |
| TW (1) | TW577738B (es) |
| WO (1) | WO2000021525A2 (es) |
| ZA (1) | ZA200103001B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| ATE418979T2 (de) | 2000-06-09 | 2009-01-15 | Lek Pharmaceuticals | Stabilisiertes arzneimittel und arzneizubereitung |
| ES2284709T3 (es) * | 2000-09-29 | 2007-11-16 | Solvay Pharmaceuticals B.V. | Formulacion farmaceutica de liberacion sostenida independiente de la fuerza ionica. |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| WO2004024184A1 (ja) * | 2002-09-11 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 徐放性製剤 |
| JP2007523664A (ja) | 2003-04-23 | 2007-08-23 | フェリング ベスローテン フェンノートシャップ | 医薬組成物用サシェ |
| US8987322B2 (en) | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| CA2615941A1 (en) * | 2005-08-05 | 2007-02-15 | Orbus Pharma Inc. | Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| BRPI0708191A2 (pt) * | 2006-02-24 | 2012-05-29 | Teva Pharma | " composições farmacêuticas de fluvastatina sódica " |
| RU2342144C1 (ru) * | 2007-04-05 | 2008-12-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтический состав, обладающий противосудорожным и психотропным действием |
| RU2356532C2 (ru) * | 2007-06-01 | 2009-05-27 | Открытое Акционерное Общество "Отечественные Лекарства" | Фармацевтическая композиция проксодолола с контролируемым высвобождением |
| CN102805739B (zh) * | 2012-04-10 | 2013-08-14 | 宋芸 | 氟伐他汀钠缓释包衣滴丸及其制备方法 |
| EP2943186A1 (en) * | 2013-01-09 | 2015-11-18 | Edgemont Pharmaceuticals LLC | Controlled release formulations of lorazepam |
| CN106344535B (zh) * | 2016-08-29 | 2019-09-20 | 济南康和医药科技有限公司 | 一种氟伐他汀钠微孔渗透泵控释片及其制备方法 |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| WO2019113084A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| US11802103B2 (en) | 2018-09-25 | 2023-10-31 | Ponce De Leon Health Designated Activity Company | Process of making calcium alpha-ketoglutarate |
| MX2021014774A (es) | 2019-06-04 | 2022-02-03 | Sunovion Pharmaceuticals Inc | Formulaciones de liberacion modificada y usos de las mismas. |
| EP3980001B1 (en) * | 2019-06-10 | 2025-08-27 | Ponce de Leon Health Designated Activity Company | Sustained-release compositions of alpha-ketoglutarate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
| CA2045428A1 (en) * | 1990-06-26 | 1991-12-27 | Alfred W. Alberts | Method for enhancing the lowering of plasma cholesterol levels |
| ZA959221B (en) * | 1994-11-02 | 1997-04-30 | Janssen Pharmaceutica Nv | Cisapride extended release |
| US5798375A (en) * | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
| GB9523752D0 (en) * | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
| DE69625046T2 (de) * | 1995-12-22 | 2003-04-10 | Kowa Co., Ltd. | Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium |
| SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
-
1999
- 1999-10-05 CO CO99062951A patent/CO5140079A1/es unknown
- 1999-10-12 PT PT99947489T patent/PT1121116E/pt unknown
- 1999-10-12 CN CNB998120812A patent/CN1196481C/zh not_active Expired - Lifetime
- 1999-10-12 AU AU60909/99A patent/AU765475B2/en not_active Expired
- 1999-10-12 EP EP99947489A patent/EP1121116B1/en not_active Revoked
- 1999-10-12 PE PE1999001027A patent/PE20001110A1/es not_active IP Right Cessation
- 1999-10-12 WO PCT/EP1999/007627 patent/WO2000021525A2/en not_active Ceased
- 1999-10-12 HK HK02102698.9A patent/HK1040920B/zh not_active IP Right Cessation
- 1999-10-12 CA CA002346868A patent/CA2346868C/en not_active Expired - Lifetime
- 1999-10-12 IL IL14237599A patent/IL142375A0/xx unknown
- 1999-10-12 DE DE69937891T patent/DE69937891T2/de not_active Expired - Lifetime
- 1999-10-12 BR BR9911648-0A patent/BR9911648A/pt not_active Application Discontinuation
- 1999-10-12 TR TR2001/01088T patent/TR200101088T2/xx unknown
- 1999-10-12 ES ES99947489T patent/ES2297936T3/es not_active Expired - Lifetime
- 1999-10-12 RU RU2001111882/15A patent/RU2259826C2/ru active
- 1999-10-12 AR ARP990105146A patent/AR020780A1/es not_active Application Discontinuation
- 1999-10-12 HU HU0104268A patent/HUP0104268A3/hu not_active Application Discontinuation
- 1999-10-12 PL PL348109A patent/PL198850B1/pl unknown
- 1999-10-12 SK SK509-2001A patent/SK286595B6/sk not_active IP Right Cessation
- 1999-10-12 NZ NZ511010A patent/NZ511010A/en not_active IP Right Cessation
- 1999-10-12 SK SK5054-2008A patent/SK286596B6/sk not_active IP Right Cessation
- 1999-10-12 DK DK99947489T patent/DK1121116T3/da active
- 1999-10-12 AT AT99947489T patent/ATE382345T1/de active
- 1999-10-12 ID IDW20010807A patent/ID29350A/id unknown
- 1999-10-12 JP JP2000575501A patent/JP2002527388A/ja active Pending
- 1999-10-12 KR KR10-2001-7004708A patent/KR100517090B1/ko not_active Expired - Lifetime
- 1999-10-13 MY MYPI99004430A patent/MY121105A/en unknown
- 1999-10-14 TW TW088117692A patent/TW577738B/zh not_active IP Right Cessation
-
2001
- 2001-04-02 IL IL142375A patent/IL142375A/en not_active IP Right Cessation
- 2001-04-04 NO NO20011695A patent/NO327285B1/no not_active IP Right Cessation
- 2001-04-11 ZA ZA200103001A patent/ZA200103001B/en unknown
-
2006
- 2006-08-14 JP JP2006221194A patent/JP4938383B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-04 CY CY20081100134T patent/CY1107874T1/el unknown
- 2008-11-11 AR ARP080104921A patent/AR069281A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5140079A1 (es) | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo | |
| AR017979A1 (es) | Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento | |
| ATE321533T1 (de) | Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen | |
| BR0312870A (pt) | Comprimido de liberação sustentada compreendendo reboxetina | |
| CO5560580A2 (es) | Formulaciones de sucralosa para disumular sabores desagradables | |
| ATE515949T1 (de) | Süssware | |
| KR870003781A (ko) | 지효성 조성물 | |
| BR0316310A (pt) | Composições farmacêuticas tendo um veìculo modificado | |
| AR030276A1 (es) | Preparacion sustancialmente homogenea de proteina estimuladora de eritropoyetina (nesp) modificada quimicamente, composicion farmaceutica y uso para la fabricacion de un medicamento para tratar un desorden hematopoyetico | |
| DK0736004T3 (da) | (2,4-disulfophenyl)-N-t-butylnitron, salte heraf og deres anvendelse som indfangningsmidler til farmaceutiske radikaler | |
| CO5261582A1 (es) | Composiciones de valdecoxib | |
| SV2002000969A (es) | Composicion parenteral reconstituible | |
| ES2097787T3 (es) | Composicion farmaceutica para la administracion rectal de principios activos que presenta una accion de medicacion prevalentemente topica a nivel del colon. | |
| ATE251449T1 (de) | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe | |
| CO4940403A1 (es) | Formulaciones de liberacion prolongada de derivados de eri- tromicina | |
| ES2570856T3 (es) | Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros | |
| KR960000247A (ko) | 사이클로스포린a 함유 조성물 및 그의 제조방법 | |
| KR880009634A (ko) | 슈도에페드린 브롬페니라민 요법의 개량 | |
| AR015482A1 (es) | Una composicion farmaceutica solida y soluble en agua que contiene un taxoide y una ciclodextrina, sus soluciones en disolventes acuosos para usoparenteral, un procedimiento para su preparacion, un metodo para prevenir la autoagregacion y la precipitacion prematura de un taxoide del grupo delpaclita | |
| RU2001111882A (ru) | Фармацевтическая композиция с замедленным высвобождением фармацевтичесКи активного вещества и способ высвобождения фармацевтически активного вещества | |
| WO2006026504A3 (en) | Mucoadhesive oral formulations of high permeability, high solubility drugs | |
| CL2008003938A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). | |
| AR047205A1 (es) | Composiciones oftalmicas que contienen una combinacion sinergica de tres polimeros | |
| BR0215187A (pt) | Composições farmacêuticas que compreendem uma ciclosporina, um tensoativo hidrofìlico e um tensoativo lipofìlico | |
| AR043071A1 (es) | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |